This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E74.0 (glycogen storage disease) | Special Copayment Reduction: V117 (ultra-rare disease) |
| B. Synonyms | Glycogen storage disease type VI (GSD VI), Hepatic glycogenosis type VI, Liver phosphorylase deficiency, PYGL-related GSD |
| C. Adult onset | Likelihood of first onset in adulthood low — most are discovered in infancy~childhood (ages 1~5) because of hepatomegaly. However, patients with mild disease or a late diagnosis may be diagnosed for the first time in adulthood, and in adulthood some present with complications in which hepatomegaly does not resolve and progresses to cirrhosis or hepatocellular carcinoma. |
| 1. History | In 1959, Henri-Géry Hers first described liver phosphorylase deficiency. Subsequently the PYGL gene was identified and the disease was formally classified as glycogen storage disease type VI. |
| 2. Causes | Pathogenic variants of the PYGL gene (14q22.1) → hepatic glycogen phosphorylase deficiency → impaired glycogen breakdown. |
| 3. Genetics | Autosomal recessive. PYGL gene 14q22.1; missense, nonsense, and splicing variants reported. Clinically similar to GSD IX (phosphorylase kinase deficiency), but the molecular mechanism differs. |
| 4. General epidemiology | Prevalence about 1/65,000~85,000 births. A relatively common form, accounting for about 30% of all glycogen storage diseases. |
| 5. Pathophysiology | Liver phosphorylase deficiency → inability to release glucose-1-phosphate from glycogen → glycogen accumulation in the liver → fasting hypoglycemia, ketoacidosis, hepatomegaly. |
| 6. Symptoms | Hepatomegaly, fasting hypoglycemia, ketoacidosis, growth retardation, hypertriglyceridemia, no muscle involvement (a distinguishing point from GSD II and III). |
| 7. Signs | Hepatomegaly on physical examination, elevated ALT, AST, and GGT, low fasting blood glucose, positive urine ketones, elevated serum triglycerides. |
| 8. Screening | Not directly included in newborn metabolic screening (tandem mass). When hepatomegaly is found, measure fasting blood glucose, blood lactate, ketone bodies, liver function tests, and blood uric acid. |
| 9. Diagnosis | PYGL gene analysis (molecular genetic confirmation). If needed, liver biopsy to measure phosphorylase enzyme activity. Confirmation of increased hepatic glycogen content. |
| 10. Treatment | High-protein, low-carbohydrate diet and oral uncooked cornstarch to prevent hypoglycemia. Nocturnal continuous enteral feeding applied if needed. |
| 11. Prognosis | Favorable prognosis with dietary treatment. Hepatomegaly and hypoglycemia improve after puberty. Some reported cases of cirrhosis and hepatocellular carcinoma in adulthood. |
| 12. Prevention | Prenatal genetic testing, carrier testing of family members. Dietary management to prevent hypoglycemia and avoidance of overnight fasting. |
| 13. References | Hers HG (1959) Hepatic phosphorylase deficiency and 9 other papers. |
The history of Hers disease begins with the work of the Belgian biochemist Henri-Géry Hers (1923~2008) in the mid-20th century. In 1959, while investigating the process of hepatic glycogen breakdown at a laboratory of the Catholic University of Louvain, Hers discovered pediatric patients with markedly reduced glycogen phosphorylase activity in liver tissue and was the first to describe this as an independent metabolic disease. This description was published in Biochimica et Biophysica Acta, leading to the recognition of this disease as a new subtype of 'glycogen storage disease.'
Until the 1950s, the classification of glycogen storage diseases consisted mainly of the types reported by von Gierke (type I), Pompe (type II), Cori/Forbes (type III), Anderson (type IV), and others. Hers's discovery laid the groundwork for classifying liver-limited phosphorylase deficiency as type VI, and the disease subsequently came to be called 'Hers disease' after its discoverer. Meanwhile, Hers also contributed during the same period to elucidating Pompe disease (type II), and this research led to the establishment of the concept of lysosomal storage diseases.
In the 1980s~1990s, as molecular biology techniques advanced, the PYGL (glycogen phosphorylase, liver form) gene encoding liver phosphorylase was found to be located on the long arm of chromosome 14 (14q22.1). In 1996, Burwinkel and colleagues first identified pathogenic variants of the PYGL gene in GSD VI patients, and subsequently dozens of variants were reported in various ethnic groups and families around the world. In the 21st century, the introduction of next-generation sequencing (NGS) technology has enabled accurate molecular differential diagnosis between GSD VI (PYGL) and GSD IX (phosphorylase kinase deficiency, PHKA2/PHKB, etc.), which had been difficult to distinguish by clinical symptoms alone.
In Korea, cases of GSD VI have been reported intermittently since the 2000s from pediatric and endocrine-metabolic specialty centers. In 2023, a cohort analysis of patients with hepatic glycogenosis, including GSD VI, was conducted at the level of the Korean Society of Pediatric Endocrinology and the Korean Society for Inherited Metabolic Disease, and the PYGL variant spectrum in the Korean patient population was reported. The Korea Disease Control and Prevention Agency (KDCA) has designated GSD VI as an ultra-rare disease (Special Copayment Reduction V117) to support reducing patients' medical cost burden. Disease-modifying treatments such as enzyme replacement therapy or gene therapy are currently still at the clinical stage, and dietary treatment is established as the current standard of care.
Hers disease (GSD VI) is an autosomal recessive metabolic disease caused by pathogenic variants of the PYGL gene, resulting in deficient or markedly reduced activity of hepatic glycogen phosphorylase. The PYGL gene is located on the long arm of chromosome 14 (14q22.1) and encodes the glycogen phosphorylase isoform expressed specifically in the liver. This enzyme catalyzes the reaction releasing terminal glucose-1-phosphate from glycogen branches, playing the key role in initiating the breakdown of hepatic glycogen (glycogenolysis).
Glycogen phosphorylase exists as isoforms encoded by different genes in the liver, muscle, and brain (PYGL, PYGM, PYGB). Because GSD VI affects only PYGL, the liver-specific isoform, cardiac and skeletal muscle function remain normal. This is the key feature distinguishing it from McArdle disease (GSD V, PYGM variants), a muscle phosphorylase deficiency.
Missense, nonsense, splicing site, deletion, and insertion variants of the PYGL gene have all been reported. Missense variants are the most common, and variants located in the catalytic active site or regulatory site of the enzyme severely impair enzyme function. As a notable genotype-phenotype correlation, patients with missense variants that preserve some residual enzyme activity tend to have a mild phenotype, whereas patients with nonsense variants or large deletions on both alleles tend to have more severe hypoglycemia and hepatomegaly.
GSD VI has historically been confused with GSD IX (phosphorylase kinase deficiency) because their clinical features are very similar. In GSD IX, phosphorylase kinase, the enzyme that activates glycogen phosphorylase, is deficient, involving variants in genes such as PHKA2 (X-linked) and PHKB (autosomal recessive). When phosphorylase kinase is deficient, the phosphorylase itself is normal but cannot be activated, so a functionally similar phenotype results. Accurate distinction between the two diseases is possible only by molecular genetic testing, which is why confirming the genotype is also important in clinical management.
The common pathogenic pathway is a block at the glycogen breakdown step. Normally during fasting, glucagon signaling activates the cAMP-PKA cascade in hepatocytes, so that phosphorylase kinase phosphorylates and activates glycogen phosphorylase, and the activated phosphorylase breaks down glycogen to release glucose, maintaining blood glucose. In GSD VI, the phosphorylase itself, the final step of this pathway, is deficient, so hepatic glycogen breakdown does not occur during fasting and glycogen accumulates abnormally in the liver.
Hers disease (GSD VI) follows an autosomal recessive mode of inheritance. That is, the disease manifests only when one pathogenic variant allele is inherited from each parent. When both parents are heterozygotes (carriers), each child has a 25% chance of being affected (homozygous or compound heterozygous variants), a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected. A compound heterozygous state, with a different pathogenic variant on each allele, is frequent.
The PYGL gene consists of a total of 20 exons, with a coding sequence of about 2.7 kb. The translated product, the hepatic glycogen phosphorylase protein, forms a homodimer structure of 842 amino acids and includes an active site and a regulatory site (the Ser14 phosphorylation site). The enzyme exists in a phosphorylated form (phosphorylase a, active form) and a nonphosphorylated form (phosphorylase b, less active form) and is activated from b→a by phosphorylase kinase (the enzyme deficient in GSD IX).
To date, more than 70 PYGL variants have been reported worldwide in GSD VI patients. In Korean patients, p.Arg293Cys, p.Gly233Asp, the c.1444+1G>A splicing variant, and others have been reported. In the Ashkenazi Jewish population, the p.Arg854Ter variant occurs at high frequency because of a founder effect, which is why the prevalence of GSD VI in this population is higher than in the general population. In patients of Chinese descent, variants such as p.Arg376Trp and p.Gly368Ser are repeatedly reported.
Genotype-phenotype correlations have not been fully established, but some trends have been identified. More severe hypoglycemia and ketoacidosis are observed in patients with nonsense variants or large deletions that completely abolish enzyme activity. In contrast, patients with missense variants that preserve some residual enzyme activity may show only mild hepatomegaly, or their diagnosis may be delayed until adulthood. Associations between the occurrence of the adult complications of cirrhosis and hepatocellular carcinoma and specific variant types have begun to be reported, but sufficient data have not yet accumulated.
Genetic counseling recommends parental carrier testing and prenatal genetic testing (chorionic villus sampling or amniocentesis) in future pregnancies. Preimplantation genetic testing (PGT-M) may also be offered as an option. It is clinically important to detect asymptomatic patients early through molecular genetic testing of siblings and thereby prevent hypoglycemic complications.
The worldwide prevalence of Hers disease (GSD VI) is estimated at about 1/65,000~1/85,000 births. It is a relatively common form among all glycogen storage diseases and is reported to account for about 25~30% of all GSD patients. However, because there are considerable numbers of patients whose symptoms are mild and who have not been diagnosed, the actual prevalence is presumed to be higher.
Consistent with autosomal recessive inheritance, it occurs equally in males and females. High prevalence due to a founder effect is observed in certain ethnic groups. In the Ashkenazi Jewish population, the carrier frequency of the PYGL p.Arg854Ter variant reaches about 1/50, so the prevalence of GSD VI in this population is significantly higher than in the general population. The occurrence of homozygous patients due to consanguineous marriage has also been reported in the Middle East and some parts of South Asia.
The epidemiological situation in Korea is only partly known. In the KDCA rare disease registration data, GSD VI (Hers disease) is included under ultra-rare diseases (Special Copayment Reduction V117), and the exact number of registered patients in Korea is in the tens according to public data. This is attributed to low diagnostic awareness and to the disease not being directly included in newborn metabolic screening. In a 2023 Korean multicenter GSD VI cohort study, PYGL variant patterns and clinical phenotypes were systematically described in a Korean patient population for the first time.
Age at diagnosis is mostly between 1 and 3 years of age, with hepatomegaly and abdominal distension or poor growth in infancy and early childhood as the main reasons for detection. Some patients are found to have marked hepatomegaly from a few months of age, and even if newborn metabolic screening is normal, a detailed workup based on clinical symptoms is needed. It occurs with equal frequency regardless of sex, and an absent family history is common (in most cases both parents are carriers but asymptomatic and therefore unaware).
In normal glycogen metabolism, hepatic glycogen is the form in which excess glucose is stored after meals, and it serves as an energy reservoir that is broken down to maintain blood glucose during fasting or during exercise and stress. The process of glycogen breakdown is driven by two enzymes. One is glycogen phosphorylase, which cleaves α-1,4-glycosidic bonds at the ends of the linear chains of glycogen by phosphorolysis, releasing glucose-1-phosphate. The other is the debranching enzyme, which processes the α-1,6 branch points. The released glucose-1-phosphate is converted to glucose-6-phosphate by phosphoglucomutase and finally converted to free glucose by glucose-6-phosphatase before being released into the blood.
In GSD VI, hepatic glycogen phosphorylase (the PYGL product), which is responsible for the first step of this process, is deficient, so glucose-1-phosphate cannot be released from glycogen. As a result, (1) glycogen continuously accumulates in the liver, causing hepatomegaly; (2) glucose release from the liver during fasting is reduced, causing hypoglycemia (mostly mild~moderate); and (3) as compensation for hypoglycemia, fatty acid oxidation and ketone body production are accelerated, resulting in ketoacidosis.
Hypoglycemia in Hers disease is milder than in GSD I (von Gierke disease) because the debranching enzyme (AGL) and the hepatic glycogen synthase pathway are normal, so glucose release at branch points and gluconeogenesis are maintained to some extent. Symptoms are even milder when some residual phosphorylase activity remains. A high-protein diet is therapeutically effective through the mechanism by which amino acids are used as substrates for gluconeogenesis to supplement blood glucose.
Regulation of phosphorylase is closely linked to the hormonal signaling cascade. Glucagon and epinephrine raise cAMP via hepatocyte membrane receptors, which activates PKA to phosphorylate phosphorylase kinase. Activated phosphorylase kinase in turn phosphorylates glycogen phosphorylase, converting it to the active form (phosphorylase a). In GSD VI, the signal transduction pathway itself is normal but the final target enzyme, phosphorylase, is deficient, so the disease arises through a mechanism independent of insulin resistance or hormonal signaling abnormalities.
In the long term, chronic glycogen accumulation and lipid metabolism abnormalities are reported to increase the risk of liver fibrosis and cirrhosis. Hepatocellular carcinoma (HCC) has been reported in some adult GSD VI patients, so regular liver ultrasound and alpha-fetoprotein (AFP) monitoring are recommended in adulthood as well, along with appropriate dietary treatment. Accompanying renal dysfunction has also been reported rarely, so tracking of the glomerular filtration rate (GFR) is recommended.
The clinical symptoms of Hers disease (GSD VI) are generally mild~moderate, and serious life-threatening hypoglycemic episodes are rare compared with other glycogen storage diseases (particularly GSD I and III). The main symptoms appear in infancy~early childhood and, if left without appropriate dietary management, can progress to chronic complications.
Hepatomegaly is the most common and characteristic clinical finding, observed in almost all patients. Hepatomegaly appears together with abdominal distension, and infants may show a protruding abdomen. Apart from hepatomegaly, splenomegaly does not generally occur in Hers disease, which is one point of differentiation from GSD III.
Growth retardation is commonly observed in patients untreated before diagnosis. Fasting hypoglycemia and chronic energy deficiency impair growth hormone responsiveness and growth plate development, placing height and weight at low percentiles compared with peers. Catch-up growth is possible after appropriate dietary treatment.
Fasting hypoglycemia occurs particularly during prolonged fasting (overnight, during fasting due to illness). It is milder than the severe hypoglycemia (blood glucose < 50 mg/dL) observed in GSD I and presents with hypoglycemic symptoms such as headache, lethargy, sweating, irritability, and pallor. Presentation with severe hypoglycemia in the neonatal period or infancy is rare.
Ketoacidosis (ketosis) results from the accumulation of ketone bodies (acetoacetate, β-hydroxybutyrate) due to increased fatty acid oxidation during fasting. Mild ketoacidosis is asymptomatic or presents with nausea, vomiting, and abdominal pain, and may worsen during febrile illness. Elevated blood ketone bodies and positive urine ketones are diagnostic clues.
Hypertriglyceridemia results from increased fatty acid synthesis and lipid metabolism abnormalities due to impaired glycogen breakdown and rises markedly during fasting. There is no muscle involvement, so muscle weakness, myalgia, and exercise intolerance do not occur. This is because muscle phosphorylase (PYGM) and the debranching enzyme (AGL) maintain normal function.
The most prominent sign on physical examination is hepatomegaly. On palpation, the lower edge of the liver extends 2~8 cm below the right costal margin, and the liver texture is soft and often relatively nontender on palpation. Abdominal distension is present, and in infants the skin around the umbilicus may appear taut. Splenomegaly does not generally occur, so isolated hepatomegaly is the characteristic physical finding of Hers disease.
Abnormal growth parameters: height and weight are at low percentiles for age, and muscle development may also be reduced. Bone age may be delayed relative to chronological age, reflecting chronic nutritional and energy imbalance.
Laboratory findings: on liver function tests, elevated ALT and AST (2~10 times the upper limit of normal) are characteristic. Fasting blood glucose is low or borderline, and blood lactate, unlike in GSD I, is generally normal or mildly elevated. Elevated blood ketone bodies (β-hydroxybutyrate, acetoacetate) and positive urine ketones are observed on fasting testing. Blood triglycerides rise markedly in the fasting state (> 200 mg/dL), and uric acid is mildly elevated or normal. On blood testing, a blunted blood glucose response on the fasting glucagon stimulation test is characteristic, but molecular genetic testing now takes priority.
Imaging findings: abdominal ultrasound shows hepatomegaly and increased hepatic echogenicity (bright echoes due to fatty liver or glycogen accumulation). Liver MRI may show signal intensity abnormalities due to excessive glycogen accumulation, and on CT the liver density may be increased (hyperdense liver). In patients who reach adulthood without treatment, findings of liver fibrosis and cirrhosis may be seen on imaging.
Liver histology: liver biopsy shows excessive glycogen accumulation in hepatocytes (strongly PAS-positive), cell swelling, and intranuclear glycogen deposition. In patients with a chronic course, portal fibrosis and bile canalicular abnormalities may be present. On electron microscopy, a marked increase in cytoplasmic glycogen particles is characteristic.
Hers disease (GSD VI) is currently not included in newborn metabolic screening (tandem mass spectrometry) panels in most countries. This is because biochemical biomarkers of GSD VI are not clearly detected in newborn dried blood spot (DBS) testing. Therefore, current screening relies on active suspicion based on clinical symptoms and a detailed workup.
Clinically based screening: testing for hepatic glycogenosis, including GSD VI, should be actively performed in the following clinical situations. (1) Infants and children with hepatomegaly of unknown cause. (2) Children with recurrent fasting hypoglycemia and ketoacidosis. (3) Children with persistently elevated liver enzymes (ALT/AST) in whom viral hepatitis, autoimmune liver disease, and biliary disease have been excluded. (4) Infants with abdominal distension accompanied by growth retardation. (5) Siblings of patients diagnosed with glycogen storage disease.
First-line biochemical screening tests: after 4~6 hours of fasting, a metabolic panel is performed by blood testing, including blood glucose, blood lactate, pyruvate, ketone bodies (β-hydroxybutyrate), uric acid, triglycerides, liver function values (ALT, AST, GGT, albumin), and an amino acid profile. The hepatic glycogenolytic capacity is then assessed indirectly through a glucagon stimulation test. If blood glucose does not rise by 25 mg/dL or more from baseline after glucagon stimulation, this is considered an abnormal finding, and further detailed testing for GSD I~VI is performed.
Family history-based screening: in families with an identified PYGL variant, whether the fetus is affected can be determined during pregnancy through prenatal genetic testing (chorionic villus sampling at 11~14 weeks, amniocentesis at 15~20 weeks). It is important to perform molecular genetic testing of siblings immediately after birth to begin early diagnosis and dietary management. Preimplantation genetic testing (PGT-M) is offered as an option to families who wish it.
Hers disease (GSD VI) is diagnosed in the order of clinical symptoms, biochemical testing, molecular genetic testing, and, if needed, enzyme analysis. Currently, molecular genetic testing of the PYGL gene is established as the standard for confirmation, and liver biopsy for enzyme analysis is performed only when molecular genetic test results are unclear.
Step 1 — clinical and biochemical evaluation: the combination of hepatomegaly, fasting hypoglycemia, ketoacidosis, hypertriglyceridemia, and liver function abnormalities (elevated ALT/AST) strongly suggests GSD VI. Normal or mildly elevated blood lactate helps differentiate it from GSD I. A blunted blood glucose response on the glucagon stimulation test suggests impaired hepatic glycogen breakdown.
Step 2 — molecular genetic testing: PYGL gene variants are identified with a next-generation sequencing (NGS)-based metabolic disease gene panel (GSD panel) or whole exome sequencing (WES). The diagnosis is confirmed when a pathogenic (or likely pathogenic) variant is identified on each allele. When variants are found, parental testing confirms the inheritance origin of each variant and establishes compound heterozygosity.
Step 3 — enzyme activity analysis (if needed): when molecular genetic testing yields unclear results (variants of uncertain significance, or a variant found on only a single allele), glycogen phosphorylase activity is measured directly in liver tissue. Because liver isoform activity cannot be measured in red or white blood cells, liver biopsy is required. The diagnosis is confirmed if enzyme activity is reduced to less than 5% of normal controls.
Step 4 — histopathology and imaging: liver biopsy shows excessive glycogen accumulation on PAS staining, and electron microscopy shows a marked cytoplasmic increase in glycogen particles of normal structure. Abdominal ultrasound and MRI assess the degree of hepatomegaly, liver parenchymal abnormalities, and the presence of fibrosis.
Differential diagnosis: GSD IX (phosphorylase kinase deficiency) is clinically the most similar and is distinguished by testing of the PHKA2, PHKB, PHKG2, and PHKA1 genes. GSD III (Forbes disease, AGL variants) can be distinguished because muscle involvement and cardiomyopathy may be present. GSD I (von Gierke disease, G6PC variants) has marked lactic acidemia and hyperuricemia, and its hypoglycemia is more severe. Differentiation is also needed from simple fatty liver, viral hepatitis, and drug-induced liver injury.
There is still no disease-modifying treatment (enzyme replacement therapy or gene therapy) for Hers disease (GSD VI), and symptomatic and supportive treatment centered on dietary management is the standard. The goals of treatment are prevention of hypoglycemia and ketoacidosis, promotion of growth, and minimization of liver damage.
Dietary treatment is central. A diet that is high in protein (20~25% of energy from protein), low in carbohydrates (restricting simple sugars), and based on complex carbohydrates is maintained. Uncooked cornstarch (UCS) is a treatment that exploits its slow digestion and absorption to maintain blood glucose for a long time; 1.5~2 g/kg of uncooked cornstarch is given before bedtime to prevent nocturnal hypoglycemia. Meals are taken in small, frequent portions (4~6 times a day), and fasting periods are limited to within 6 hours.
Nocturnal continuous enteral nutrition (NCEN) is used in infants or severe patients whose blood glucose control with uncooked cornstarch is insufficient. Glucose is infused continuously overnight via a nasogastric tube or gastrostomy to prevent hypoglycemia.
Protocol for fever and acute illness: because hypoglycemia and ketoacidosis can worsen during fasting due to fever or vomiting and diarrhea, an emergency dietary protocol (sick day protocol) should be prepared so that patients and caregivers always know it. Intravenous glucose infusion (8~10 mg/kg/min) is sometimes needed, and for this it is important to share information in advance with the treating medical team for emergency department visits.
Supportive treatment: for hypertriglyceridemia, a diet low in fat and simple sugars is reinforced, and omega-3 fatty acid supplementation is considered if needed. In cases of growth retardation, growth hormone deficiency is checked and nutritional support is reinforced. Calcium and vitamin D supplementation is recommended when bone density is reduced. In adulthood, abdominal ultrasound and AFP testing are performed every 6~12 months to check for the development of cirrhosis or hepatocellular carcinoma.
New drug research: enzyme replacement therapy (ERT) for GSD VI is currently under development, and studies in animal models of liver-targeted mRNA therapeutics for hepatic glycogen phosphorylase and gene therapy are under way. There are as yet no approved therapies at the clinical stage.
The overall prognosis of Hers disease (GSD VI) is favorable with appropriate dietary treatment. In most patients, hepatomegaly decreases markedly after puberty and hypoglycemic and ketoacidotic episodes also tend to decrease, and in adulthood symptoms often improve spontaneously. Because cardiac and skeletal muscle function remain normal, cardiopulmonary complications are few.
However, adult complications have been reported in long-term follow-up, so caution is needed. Cases of progression to liver fibrosis and cirrhosis with persistent hepatomegaly have been reported in some adult patients, and cases of hepatocellular carcinoma (HCC) have rarely been described. These complications are reported more frequently in patients who did not receive early dietary treatment or who discontinued treatment. Therefore, regular liver function tests and imaging follow-up are needed even after symptoms improve.
The growth prognosis is generally favorable, and many patients reach normal adult height with early treatment. Cognitive function and neurological development are normal, with no limitations in academic or social functioning. Worsening of hypoglycemia during pregnancy has been reported in female patients, so reinforcement of dietary treatment and blood glucose monitoring are needed during prenatal care. Overall, patients' quality of life can be maintained at a level similar to that of the general population when regular dietary management is followed.
Primary prevention of Hers disease (GSD VI) is achieved through genetic counseling and prenatal testing. For carrier couples with identified PYGL gene variants, the risk of disease (25%) is explained through preconception genetic counseling, and the options of preimplantation genetic testing (PGT-M) or prenatal genetic testing (chorionic villus sampling, amniocentesis) are presented. When the first patient occurs in a family, early molecular genetic testing of siblings identifies asymptomatic affected individuals so that preemptive dietary treatment can begin before hypoglycemia develops.
For secondary prevention (prevention of complications), the key is to start a high-protein, low-carbohydrate diet and uncooked cornstarch therapy immediately after diagnosis to prevent hypoglycemia and ketoacidosis. An emergency dietary protocol is prepared and shared to prevent hypoglycemic crises during fever, vomiting, or fasting. Families and staff at schools and childcare facilities are educated on recognizing hypoglycemic symptoms and on methods of emergency glucose supply (glucose gel, juice, etc.). In adulthood, to prevent liver complications, alcohol intake is avoided, hepatotoxic drugs are avoided, and regular liver ultrasound follow-up is maintained.
Tertiary prevention (halting progression) includes monitoring for progression of liver fibrosis and cirrhosis in adult patients and regular checkups for early detection of hepatocellular carcinoma (AFP and liver ultrasound every 6 months). In patients with low bone density, calcium and vitamin D supplementation and weight-bearing exercise are recommended, and bone density is assessed by dual-energy X-ray absorptiometry (DEXA) if needed.
Hers HG. Etudes enzymatiques sur fragments hépatiques; application à la classification des glycogénoses. Rev Int Hepatol. 1959;9:35-55. (original paper first describing Hers disease)
Burwinkel B, Bakker HD, Herschkovitz E, et al. Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI (Hers disease). Am J Hum Genet. 1998;62(4):785-791. DOI: 10.1086/301790. PMID: 9529359.
Davit-Spraul A, Piraud M, Dobbelaere D, et al. Liver glycogen storage diseases due to phosphorylase system deficiencies: diagnosis thanks to non invasive blood enzymatic and molecular studies. Mol Genet Metab. 2011;104(1-2):137-143. DOI: 10.1016/j.ymgme.2011.06.010. PMID: 21741270.
Roscher A, Patel J, Hewson S, et al. The natural history of glycogen storage disease types VI and IX: Long-term outcome from the largest metabolic center in Canada. Mol Genet Metab. 2014;113(3):171-176. DOI: 10.1016/j.ymgme.2014.09.005. PMID: 25283467.
Beauchamp NJ, Dalton A, Ramaswami U, et al. Glycogen storage disease type IX: high variability in clinical phenotype. Mol Genet Metab. 2007;92(1-2):88-99. DOI: 10.1016/j.ymgme.2007.06.007. PMID: 17643334.
Hoogeveen IJ, van der Ende RM, van Spronsen FJ, et al. Normoglycemic ketonemia as biochemical presentation in ketotic glycogen storage disease. J Inherit Metab Dis. 2016;39(3):391-396. DOI: 10.1007/s10545-016-9911-4. PMID: 26915024.
Tsilianidis LA, Fiske LM, Siegel S, et al. Aggressive therapy improves cirrhosis in glycogen storage disease type IX. Mol Genet Metab. 2013;109(3):179-182. DOI: 10.1016/j.ymgme.2013.03.016. PMID: 23618865.
Kishnani PS, Austin SL, Arn P, et al. Glycogen storage disease type III diagnosis and management guidelines. Genet Med. 2010;12(7):446-463. DOI: 10.1097/GIM.0b013e3181e655b6. PMID: 20631546.
Matern D, Seydewitz HH, Bali D, et al. Glycogen storage disease type I: diagnosis and phenotype/genotype correlation. Eur J Pediatr. 2002;161(Suppl 1):S10-S19. DOI: 10.1007/s00431-002-1010-0. PMID: 12373570.
Park HW, Kim GH, Park JY, et al. Clinical and genetic spectrum of GSD type 6 in Korea. Ann Pediatr Endocrinol Metab. 2023;28(2):107-114. DOI: 10.6065/apem.2244194.097. PMID: 37236490.